1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novo Nordisk A/S

Novo Nordisk A/S

NONOF
Novo Nordisk A/SUS flagOther OTC
46.77
USD
+0.27
- -
207.69BMarket Cap
Novo Nordisk A/S
NONOF
(Other OTC)

Recent

price

46.77

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.47
11.73
14.23
15.6
16.94
20.99
22.09
22.58
23.11
25.7
27.2
30.65
39.06
51.81
65.2
69.56
74.23
Revenue per Share
2.48
3.02
3.91
4.7
5.05
6.78
7.5
7.71
7.98
8.2
9.03
10.4
12.26
18.67
22.67
23.06
26.24
Basic EPS, GAAP
2.72
3.19
3.39
4.16
5.22
6.2
7.91
6.57
6.66
7.49
6.4
10.36
14.16
15.62
15.64
6.52
10.77
Free Cash Flow per Basic Share
0.76
1.01
1.41
1.81
2.26
2.51
4.71
3.81
3.94
4.09
4.31
4.68
5.58
7.09
9.91
11.65
11.71
Dividend per Share
6.16
6.46
7.26
7.74
7.6
9.03
8.88
9.96
10.58
12
13.47
15.31
18.55
23.9
32.31
43.67
50.01
Book Value per Share
5.92
6.2
6.99
7.45
7.34
8.62
8.34
9.3
9.53
10.78
9.08
5.97
7.23
10.35
7.35
14.4
22.42
Tangible Book Value per Share
5,805
5,654
5,483
5,359
5,244
5,142
5,060
4,946
4,839
4,749
4,668
4,594
4,531
4,483
4,454
4,443
4,438
Basic Weighted Avg Shares
60,776
66,346
78,026
83,572
88,806
107,927
111,780
111,696
111,831
122,021
126,946
140,800
176,954
232,261
290,403
309,064
329,431
Sales/Revenue/Turnover
31.08
33.72
37.77
37.68
38.84
45.81
43.33
43.84
42.25
43.01
42.64
41.65
42.28
44.16
44.19
41.3
43.13
Operating Margin (%)
2,467
2,737
2,693
2,799
3,435
2,959
3,193
3,182
3,925
5,661
5,753
6,025
7,362
9,413
19,107
21,982
27,159
Depreciation Expense
14,403
17,097
21,432
25,184
26,481
34,860
37,925
38,130
38,628
38,951
42,138
47,757
55,525
83,683
100,988
102,434
116,443
Net Income, GAAP
21.23
22.02
22.94
22.6
22.33
19.83
20.66
21.67
18.87
19.78
20.69
19.17
19.6
20.05
20.6
21.53
21.72
Effective Tax Rate (%)
23.7
25.77
27.47
30.13
29.82
32.3
33.93
34.14
34.54
31.92
33.19
33.92
31.38
36.03
34.78
33.14
35.35
Profit Margin (%)
18,817
18,812
18,525
17,833
12,604
14,267
12,330
13,024
4,903
3,473
-4,464
-13,921
-12,746
-30,009
-55,826
-43,208
-30,387
Working Capital
504
502
- -
- -
- -
- -
- -
- -
- -
3,009
2,897
12,961
24,318
20,528
89,674
118,941
121,794
LT Debt
36,965
37,448
40,632
42,569
40,294
46,969
45,269
49,815
51,839
57,593
63,325
70,746
83,486
106,561
143,486
194,047
221,277
Total Equity
38.02
43.86
56.42
56.57
60.67
83.38
76.18
73.07
68.92
69.94
60.88
53.92
56.09
64.64
51.89
34.23
33.4
Return on Invested Capital (%)
38.78
44.68
54.07
60.12
63.27
78.41
81.2
78.76
74.52
68.39
62.53
56.11
54.03
69.28
53.86
37.02
37.19
Return on Capital (%)
39.62
45.95
54.9
60.54
63.92
79.9
82.23
80.2
76
71.19
69.7
71.24
72
88.07
80.78
60.7
59.82
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12,017
27,210
18,333
LT Borrowings
111,705
119,172
121,794
LT Finance Leases
7,236
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,443
4,438
4,425
Market Capitalization
1,445,759
1,030,270
1,371,678

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
172,453
177,317
208,696
Cash, Cash Equivalents & STI
26,962
21,626
44,982
Accounts Receivable, Net
70,856
82,565
88,949
Inventories
49,623
51,352
51,352
Total Current Liabilities
215,661
225,158
239,083
Payables & Accruals
161,523
150,202
175,252
ST Debt
12,017
27,210
18,333
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.88%
25.45%
35.24%
Free Cash Flow
4.46%
8.88%
-58.38%
Net Income, GAAP
12.21%
20.48%
1.43%
Sales/Revenue/Turnover
11.61%
19.86%
6.43%
Total Cash Common Dividend
17.67%
21.26%
17.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
65,349
68,060
71,311
85,683
290,403
2025
78,087
76,857
74,976
79,144
309,064
2026
96,823
78,488
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.7
4.5
6.13
6.35
22.67
2025
6.54
5.96
- -
6.05
23.06
2026
10.93
4.74
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.4
- -
3.5
- -
9.91
2025
7.95
-0.04
- -
- -
11.65
2026
7.95
- -
- -
- -
- -
Similar Companies
AstraZeneca PLC (AZN.ST)
Pfizer Limited (PFIZER.NS)
AbbVie Inc. (0QCV.L)
Bristol-Myers Squibb Company (BMY.SW)
PT Kalbe Farma Tbk. (KLBF.JK)
Pfizer Limited (PFIZER.BO)
Business
Novo Nordisk A/S is a leading global healthcare company focused on discovering, developing, manufacturing and marketing pharmaceutical products for serious chronic diseases, including diabetes, obesity, rare blood and endocrine disorders, haemophilia and growth hormone therapy. Founded in 1923 through predecessor companies and formally established in 1989 via the merger of Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium, the company is headquartered in Bagsværd, Denmark, with production facilities in nine countries and operations in 168 markets worldwide. Its core products encompass GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes, Wegovy for obesity and chronic weight management; insulin analogues including NovoLog/NovoRapid, Tresiba, Levemir, Fiasp and human insulins like Novolin R; haemophilia treatments such as NovoSeven and NovoEight; growth hormone therapies; hormone replacement products; and delivery systems like insulin pens, smart pens, needles and digital apps; alongside rare disease therapies for blood and endocrine conditions. Novo Nordisk maintains majority control through Novo Holdings A/S and employs over 76,000 people globally, targeting patients with type 1 and type 2 diabetes, obesity, cardiovascular risks and rare disorders. Recent developments include the February 2024 acquisition by parent Novo Holdings of Catalent for $16.5 billion, with Novo Nordisk purchasing three manufacturing sites for $11 billion to expand capacity for Wegovy and Ozempic; a planned $4.1 billion semaglutide production facility in Clayton, North Carolina, announced in June 2024; a DKK 8.5 billion investment in a new rare disease facility in Odense, Denmark, in December 2024; FDA filing in November 2025 for a higher 7.2 mg Wegovy dose under expedited review following strong STEP UP trial results; a July 2025 collaboration with WeightWatchers and launch of NovoCare Pharmacy offering Wegovy at $499 monthly; phase 2 success for amycretin in type 2 diabetes weight loss; the October 2025 acquisition of Akero Therapeutics for $5.2 billion to enter metabolic dysfunction-associated steatohepatitis treatment; and a September 2025 announcement of 9,000 workforce reductions representing 9% of staff, alongside naming Maziar Mike Doustdar as CEO effective August 2025.